Hope therapeutics™, inc. and nrx pharmaceuticals, inc. (nasdaq:nrxp) announce dr. jonathan javitt and dr. david feifel to present keynote address, beyond ketamine monotherapy: combined interventional treatment of suicidal depression and ptsd, at the 8th annual neuroscience innovation forum in san francisco

The keynote address, entitled " beyond ketamine: combined interventional treatment of suicidal depression and ptsd ," will be presented at 10:30am pt on sunday january 12th, 2025 prof. david feifel md phd, designated chief medical innovation officer of hope and founder of the kadima neuropsychiatry institute, is an international thought leader in the interventional psychiatry space nrx pharmaceuticals recently initiated filing of its nda for nrx-100 (iv ketamine) for the treatment of suicidal depression recent announcement of kadima neuropsychiatry institute and dura medical as planned cornerstone acquisitions for hope therapeutic's international network of interventional psychiatry clinics $27 million in anticipated funding for hope clinic acquisitions and pharmaceutical operations under a binding term sheet with an institutional investor miami , jan. 7, 2025 /prnewswire/ -- hope therapeutics™, inc., ("hope"), a medical and technology driven company and wholly-owned subsidiary of nrx pharmaceuticals, inc. ("nrx", and collectively with hope, the "company") (nasdaq:nrxp), today announced that jonathan javitt md mph, founder and ceo of nrx and co-ceo of hope, and prof.
NRXP Ratings Summary
NRXP Quant Ranking